Multiple Breath Washout, a Clinimetric Dataset

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

530 participants

Study Classification

OBSERVATIONAL

Study Start Date

2017-05-05

Study Completion Date

2024-03-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Monitoring patients with chronic, inflammatory airways disease particularly in the early stages is hampered by the relative insensitivity of current outcome measures to detect subtle changes. Multiple breath washout is a potential sensitive test that is a useful readout of disease at these early stages but it lacks standardisation and knowledge of variability with reference to standard lung function measures. This is a Cross sectional and longitudinal observation study. The hypothesis is that multiple breath washout-derived indices will provide a robust signal of gas mixing inhomogeneity, correlating with conventional measures of airway disease severity. Multiple breath washout performed on different devices will generate indices which correlate but differ in value.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Number of Multiple Breath Washout Tests in Adults With Pulmonary Disease and Healthy Controls

NCT03176745

Healthy Controls Chronic Obstructive Pulmonary Disease Bronchial Asthma +1 more

COMPLETED

Predictive Value of Spirometric PIF to Produce PIF Rate Needed for the Use of Current DPI's.

NCT03377920

Severe Asthma COPD

UNKNOWN NA

The Natural History of Small Airways Physiology in Diseased and Healthy States

NCT00677560

Asthma COPD Interstitial Lung Disease +2 more

COMPLETED

Physiology and Structure of the Small Airways in Patients With Chronic Airflow Obstruction or COVID-19

NCT04716023

Copd COVID-19 Asthma +1 more

UNKNOWN

The Use of Entropy to Assess Sleep Disordered Breathing in Chronic Respiratory Disease

NCT07060079

Bronchial Asthma Bronchiectasis ILD +4 more

RECRUITING

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Lung Clearance Index (LCI) has been shown to be more sensitive and perhaps more applicable in early stages of lung disease when compared to currently utilised physiological outcome measures, and yet it is not approved by regulatory agencies as a recognised surrogate outcome measure. This may highlight some of the lack of understanding within MBW; what is the best equipment to use, what is the minimal value of change to show an improvement in LCI, what is LCI's correlation with clinical outcome measures and what does the progression of LCI tell us about lung disease. These questions will be addressed with a view to contributing a body of data to guide decisions around its utility in both interventional drug trials and for monitoring in a clinical setting.

The aim of this study is to assess the suitability of LCI as a clinical outcome measure for both clinical trials and clinical monitoring of patients with inflammatory respiratory disease across the disease spectrum. Different testing modalities will be compared as well as assess the repeatability and validity of LCI for its determination as an outcome measure. Long-term follow up will allow an assessment of the relationship between LCI and future outcomes such as rate of decline in lung function and frequency of exacerbations, both recognised as relevant by regulatory agencies.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Cystic Fibrosis Primary Ciliary Dyskinesia Bronchiectasis Asthma Bronchitis Sleep Disorder

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

CROSS_SECTIONAL

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Multiple breath washout testing

Multiple breath washout testing will be completed on different devices over time

Intervention Type DEVICE

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Exhlayzer D (Ecomedics) Modified Innocor (Innovision) Amis 2000 (Respiratory Mass Spectrometer) (Innovision) EasyOne Pro (New Diagnostic Design (NDD) Medical Technologies Inc

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* For patients with the following respiratory disease, diagnosis confirmed by:
* CF: diagnosed by standard criteria
* PCD: diagnosed by ciliary beat frequency measurement, ciliary beat pattern analysis or electron microscopy of ciliary ultrastructure, or genetics
* Non-CF bronchiectasis: CT diagnosis of bronchiectasis and not fulfilling diagnostic criteria for CF or PCD
* Asthma: as diagnosed by standard diagnostic criteria of British Thoracic Society/Scottish Intercollegiate Guideline Network (BTS/SIGN) guidelines.
* Persistent bacterial bronchitis defined as a wet cough present for \>1 month, usually with bronchoscopic evidence of chronic infection, that resolves with appropriate antibiotic therapy
* Sleep Disordered Breathing.
* For healthy volunteers, these will be colleagues and staff contacts (including children) at a participating centre i.e. Royal Brompton Hospital, or will be siblings of patients.
* Written informed consent (assent from children of appropriate age) obtained.

Exclusion Criteria

* Positive culture (within the last year of / receiving treatment for Mycobaterium tuberculosis or abscessus (due to cross-infection concerns).
* Pregnant or breastfeeding.
* Inability to understand or cooperate with the test(s).
* Inability to give informed consent, or withdrawal of informed consent.

Minimum Eligible Age

2 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes